MOESM4 of Is cancer-related death associated with circadian rhythm?

Additional file 4: Figure S3. Scatter plot of the number of deaths by time in hours (A) and in minutes of the day (B), showing the temporal pattern of death due to pneumonia, Hong Kong, 2008–2016. We found no evidence of a unimodal sinusoidal circadian rhythm (periodicity) in the time of pneumonia deaths according to the parametric sinusoidal circadian test (Z = 1.94, P = 0.144). Note: Restricted cubic splines using 3 knots were fitted to model the number of deaths in each hour of the day. The resulting spline fit is graphed as a red line

MOESM3 of Is cancer-related death associated with circadian rhythm?

Additional file 3: Figure S2. Scatter plot of the number of deaths by time in hours (A) and in minutes of the day (B), showing the temporal pattern of death due to ischemic heart disease, Hong Kong, 2008–2016. We found evidence of a unimodal sinusoidal circadian rhythm (periodicity) in the time of cardiac deaths according to the parametric sinusoidal circadian test (Z = 3.97, P = 0.019). Note: Restricted cubic splines using 3 knots were fitted to model the number of deaths in each hour of the day. The resulting spline fit is graphed as a red line

MOESM2 of Is cancer-related death associated with circadian rhythm?

Additional file 2: Figure S1. Plot of the distribution of the prevalence ratios of death due to cancer, ischemic heart disease, and pneumonia by time (hour) in a day. 0:00–0:59 am is the reference hour

MOESM1 of Is cancer-related death associated with circadian rhythm?

Additional file 1. Materials and method, and model specification and formulae

Additional file 1: of Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis

Appendix S1. Electronic databases search strategy (DOCX 13 kb

Additional file 2: of Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis

Table S1. Risk of bias assessment of included studies using the Quality in Prognostic Studies tool. The six domains represent important issues to consider when evaluating the overall validity and bias in studies of prognostic factors. Some domains may not be relevant to the specific study. (DOCX 23 kb

Presentation_1_Targeted Intraoperative Radiotherapy (TARGIT-IORT) for Early-Stage Invasive Breast Cancer: A Single Institution Experience.pptx

Purpose/ObjectiveWe present our single-institution experience in the management of invasive breast cancer with targeted intraoperative radiotherapy (TARGIT-IORT), focusing on patient suitability for IORT determined by the American Society for Radiation Oncology (ASTRO) Accelerated Partial Breast Irradiation (APBI) consensus guidelines.Materials/MethodsWe identified 237 patients treated for biopsy-proven early-stage invasive breast cancer using low energy x-ray TARGIT-IORT at the time of lumpectomy between September 2013 and April 2020 who were prospectively enrolled in an institutional review board (IRB) approved database. We retrospectively reviewed preoperative and postoperative clinicopathologic factors to determine each patient’s ASTRO APBI suitability (suitable, cautionary or unsuitable) according to the 2017 consensus guidelines (CG). Change in suitability group was determined based on final pathology. Kaplan-Meier methods were used to estimate the survival probability and recurrence probability across time.Results237 patients were included in this analysis, based on preoperative clinicopathologic characteristics, 191 (80.6%) patients were suitable, 46 (19.4%) were cautionary and none were deemed unsuitable. Suitability classification changed in 95 (40%) patients based on final pathology from lumpectomy. Increasing preoperative lesion size or a body mass index (BMI) ≥ 30 kg/m2 were significant predictors for suitability group change. Forty-one (17.3%) patients received additional adjuvant whole breast radiotherapy after TARGIT-IORT. At a median follow up of 38.2 months (range 0.4 – 74.5), five (2.1%) patients had ipsilateral breast tumor recurrences (IBTR), including two (0.8%) true local recurrences defined as a recurrence in the same quadrant as the initial lumpectomy bed with the same histology as the initial tumor. IBTR occurred in 1/103 (0.09%) patient in the post-op suitable group, 4/98 (4.08%) patients in the post-op cautionary group, and no patients in the post-op unsuitable group. At 3-years, the overall survival rate was 98.4% and the local recurrence free survival rate was 97.1%.ConclusionThere is a low rate of IBTR after TARGIT-IORT when used in appropriately selected patients. Change in suitability classification pre to postoperatively is common, highlighting a need for further investigation to optimize preoperative patient risk stratification in this setting. Patients who become cautionary or unsuitable based on final pathology should be considered for additional adjuvant therapy.</p

Additional file 10 of Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

Additional file 10. List of candidate items to be discussed at the DEFINE Consensus meeting

Additional file 6 of Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

Additional file 6. SPIRIT-DEFINE and CONSORT-DEFINE items generation for Delphi survey: Table A6-1. Table A6-1. References supporting the proposed candidate items in the DEFINE Delphi survey

Additional file 8 of Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

Additional file 8. Delphi survey participants demographics and harmonisation of roles: Tables A8-1 – A8-2. Table A8-1. Demographics of Delphi survey participants. Table A8-2. Harmonisation of participants’ defined roles